Reading ICCC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ICCC free→Reading ICCC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ICCC free→QuarterlyIQ Insights · ICCC
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(0.0) + peer(0.2*2.2) + term(0.0) → 0.43% (capped ±15.0)
in 57 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition On May 14, 2026 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On April 8, 2026 ImmuCell Corporation (the "Company") issued a press release announcing a 28.4% increase in product sales in Q1 of 2026 as compared to Q1 of 2025, based on preliminary, unaudited sales results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposed of S…
shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated March 4, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document ) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 4, 2026 IMMUCELL CORPORATION By: /s/ Timothy C. Fiori Timothy C. Fiori Chief Financial Officer Exh…
Results of Operations and Financial Condition On January 8, 2026, ImmuCell Corporation (the “Company”) issued a press release announcing its preliminary, unaudited sales results for the three-month and twelve-month periods ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto, and is incorporated herein by reference. The information in this report and the exhibit attached hereto are being furnished and shall not be deemed filed for purposes of the Securities…
Results of Operations and Financial Condition On November 13, 2025 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise…
shall be deemed to be furnished, and not filed: 99.1 Press Release of the Company dated November 4, 2025. 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: November 4, 2025 By: /s/ Timothy C. Fiori Timothy C. Fiori Chief Financial Officer 2 Exh…
shall be deemed to be furnished, and not filed: 99.1 Press Release of the Company dated October 7, 2025. 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: October 7, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Executive…
shall be deemed to be furnished, and not filed: 10.1 Employment Agreement between the Company and Olivier te Boekhorst dated as of September 29, 2025. 10.2 Confidential Information, Inventions and Noncompete Agreement between the Company and Olivier te Boekhorst, signed September 29, 2025 and effective upon commencement of employment. 99.1 Press Release of the Company dated September 29, 2025. 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant…
shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated August 14, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: August 14, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief E…
shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated July 9, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: July 9, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President and Chief Exec…
shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated May 14, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: May 14, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Executi…
shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated April 8, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: April 8, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Execu…
shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated February 25, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: February 25, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President, Chi…